Kornimate/medical-research-clean huggingface dataset:
18f-flt pet for suspicious findings on mammography and breast ultrasound

Conditions: Breast Neoplasms

Summary: the purpose: to investigate the diagnostic accuracy of 18f-flt pet for the suspicious lesions on mammograms and ultrasound.

1. to investigate the diagnostic accuracy of 18f-flt pet for the suspicious lesions on mammograms and ultrasound, using the pathologic result of biopsy as gold standard, and to determine whether 18f-flt pet can increase the specificity in breast lesion diagnosis and thus reduce the unnecessary biopsy. 2. to evaluate whether 18f-flt pet is a cost-effective imaging modality for breast cancer diagnosis.

Eligibility criteria:
inclusion criteria: 1. women aged between 20 to 80 years 2. women who have localized findings on mammography and / or ultrasound and will receive biopsy. 3. the lesions on the conventional imaging measure \>=1cm 4. wbc count \>=3000/l, or platelet\>=75,000/l 5. liver function, ast or alt \< 78 u/l 6. renal function, creatinine \< 2.0 mg/dl.the laboratory examinations should be performed within 4months before our study. exclusion criteria: 1. pregnant women or who are planning to be pregnant. 2. known cancers in other organs. 3. women who are not able to cooperate with the pet/ct examination.

Keywords: flt pet breast neoplasms mammography breast ultrasound
chronic hepatitis c (chc) - genotype 3 infection in canada

Conditions: Chronic Hepatitis C - Genotype 3

Summary: hepatitis c is a small rna virus spread by blood to blood contamination. there are to date 6 known genotypes and within each there are several subtypes. although all genotypes are distributed worldwide some are more common in certain countries and/or among certain populations.

genotype 3(g3) infection is the predominant type in south east asia (bangladesh, pakistan, india and sri lanka). in addition, because of the "promiscuous exposure" to hepatitis c amongst injection drug users, it is not unusual for the latter to be infected with g3 as well. there are several subtypes of g3. viral genotype has long been recognized as a major factor influencing the response to interferon-based therapy. patients infected with g2 and g3 respond much better to current therapy with peginterferon and ribavirin than those infected with g1 and g4. most studies have grouped patients with g2 and g3 together, with few published comparisons of rates of viral clearance between these two favourable genotypes. more recently it has become evident that in all individuals with chronic hepatitis c, the presence of insulin resistance, with or without the accompanying metabolic syndrome, is a major factor which influencing the response to antiviral therapy in chc. very recently it has been reported and confirmed by several sites worldwide that specific polymorphisms of the il28 gene are closely correlated with response to antiviral therapy in genotype 1 chc. interestingly, the polymorphisms were also shown to segregate according to ethnicity and may explain, at least in part, the marked differences in treatment response between different ethnic groups.

Eligibility criteria:
inclusion criteria: * infected with only genotype 3, hepatitis c * treatment naïve before current course of therapy * age 18 or older exclusion criteria: * under age 18 * co-infection with hiv or hepatitis b or any other hcv genotype in addition to genotype 3 * prior treatment for hepatitis c aside from herbal remedies

Keywords: hepatitis c genotype 3 demographics genetics metabolic status
vitamin d plus celecoxib therapy to stimulate intratumoral immune reactivity

Conditions: Mouth Neoplasms

Summary: the poor survival of veterans with oral cancer underscores the significance of identifying new treatment approaches. the proposed studies will test a new 2 pronged immunotherapeutic approach for oral cancer patients which lessen the immune inhibitory environment while maturing cells that can stimulate t cell reactivity against oral cancer cells.

the hypothesis of this study is beneficial t cell reactivity in oral squamous cell carcinoma (oscc) tumors can be synergistically stimulated by blocking suppressor endothelial cells and their induction of other inhibitory cell populations while also maturing immune inhibitory cd34+ cells into antigen-presenting dendritic cells. to test this hypothesis, newly diagnosed oscc patients will be administered the cyclooxigenase 2 inhibitor celecoxib and/or calcitriol for the 3 week duration between cancer diagnosis and surgical treatment. the following aims will test the immunological and clinical effectiveness of the combination treatment: * 1. to block the suppressive activity of endothelial cells and increase the levels of dendritic that are stimulatory to t cell reactivity, thereby synergistically increasing intratumoral t cell reactivity. these functional immune analyses will use oscc tissues removed from untreated patients or patients treated with celecoxib and/or calcitriol. * 2. to reduce development of oscc recurrences by synergistically stimulating intratumoral t cell reactivity with celecoxib to block suppressor endothelial cell activity and calcitriol to mature cd34+ suppressor cells into t cell stimulatory dendritic cells.

Eligibility criteria:
inclusion criteria: * locoregional oscc (t stage ii-iv) of the oral cavity, oropharynx, larynx, or hypopharynx without evidence of distant metastases * greater than or equal to 18 years of age * the oscc treatment plan includes surgical resection * performance status of 0 or 1 * recovered from any prior surgery * must be willing to use appropriate contraception if of child-bearing potential * give signed informed consent prior to the initiation of therapy exclusion criteria: * prior immunotherapy * chemotherapy or radiation therapy within three weeks * concurrent nsaid treatments while undergoing treatment * women pregnant or lactating * hiv positive * have an active infection requiring antibiotic therapy, or concomitant malignancies * history of idiopathic urinary calcium stone disease, chronic hypercalcemia, or gastrointestinal malabsorptive conditions

Keywords: calcitriol celecoxib immunotherapy
risk adapted beacopp regimen for standard and high risk hodgkin lymphoma

Conditions: Classical Hodgkin Lymphoma; Nodular Sclerosis; Mixed Cellularity; Lymphocyte Depletion; Lymphocyte Rich

Summary: .this study is trying to address change of chemotherapy dosage according to individual patient response to initial cycles of chemotherapy in order to reduce cumulative dose of chemotherapy.the study includes patients with early unfavorable and advanced hodgkin lymphoma. patients with low risk were started with standard beacopp and only high risk patients were started with escalated beacopp.following 2 cycles of therapy the patients were reassessed.based on scintigraphy results decision was made regarding further therapylative chemotherapy for early responders and maximize dose intensity for late responders.

patients were eligible if they had early unfavorable disease or patients who presented with stage iii or iv disease .pt assigned to receive 6 cycles of bleomycin etoposide, doxorubicin, cyclophosphamide procarbazine, prednisone (beacopp) or increased dose beacopp. (idb). patient with stage i or ii with ³4 sites of disease, age ³50, esr³50 "b" symptoms lymphocyte depleted histology "e" site, or bulky disease were defined as early unfavorable disease and were given standard beacopp (sb). those with i, ii b or bulky disease or stage iii, iv were defined according the ips. increased dose beacopp (idb) cycles of therapy was initiated only to patients with ips of 3 or more risk factors (high risk) standard beacopp (sb) cycles were initiated to those with a score of 0-2 (standard risk). all patients had baseline ga67 or hybrid pet\\ct scan at diagnosis and post first cycle for gallium scan or second cycle for hybrid pet\\ct. upon the scan results therapy was planned and given for addition of 4 cycles. those with negative scan received cycles of sb as of the third cycle. dose was reduced to level i to iii if patient was hospitalized due to fever and neutropenia of 5 days or longer or pt had an episode of sepsis with unstable vital signs. patient with residual uptake interpreted as positive scan had additional cycles of idb for a total of 6 cycles

Eligibility criteria:
inclusion criteria: * stage i-iia/b with adverse prognostic or iii-iv disease * age 18 and over * performance status ecog 0-3 * hematopoietic wbc at least 4000/mm3(unless documented bone marrow involvement) * hepatic bilirubin no greater then 5 mg/dl * renal:creatinine no greater than 2.0mg/dl * not pregnant or nursing * fertile patients must use effective contraception * hiv negative * no other malignancy within the past 5 years exclusion criteria: -

Keywords: hodgkin lymphoma beacopp pet gallium tailored therapy
costs of postoperative nausea and vomiting in ambulatory surgery patients

Conditions: Postoperative Nausea and Vomiting

Summary: this is an observational study with the goal of determining the costs of nausea and vomiting in ambulatory patients after surgery from the us societal perspective.

the direct cost between the end of outpatient surgery and discharge from the hospital will include costs of labors and supplies for any outpatient care, physician visits, laboratory tests, and prescribed medications, which may be used to treat operation side effects. based on the time and motion study design, the timing of these healthcare activities will be collected. the study coordinator will observe the actual time taken for each activity for each patient. the observation period will begin after completion of the outpatient surgery. the start and end times for each activity performed will be recorded. therefore, each activity and its duration will be concurrently recorded. we will also query patients daily to determine additional costs associated with ponv until the third postoperative morning.

Eligibility criteria:
inclusion criteria: * male or female * 18 years of age or older * american society of anesthesiologists (asa) physical status 1 to 3 * outpatients undergoing elective surgery with anesthesia that is expected to last one hour and to require significant postoperative opioids * patients must provide written informed consent and have at least two of the following ponv risk factors: (1) female gender, (2) history of ponv and/or currently prone to motion sickness, (3) non smoking status. exclusion criteria: * any drug with potential antiemetic efficacy within 24 hours prior to the anesthetic procedure * vomiting, retching, or nausea in the 24 hours preceding anesthesia * body mass index \>40.

Keywords: outpatient surgery postoperative nausea and vomiting costs observational
perioperative examination of inflammatory markers in relation to sentinel lymph node biopsy in patients with melanoma; a pilot study

Conditions: Melanoma; Surgery

Summary: we want to test if an association between sentinel lymph node biopsy (slbn) and a systemic inflammatory response can be made.

sentinel lymph node biopsy (slbn) is essential in staging melanoma and properly selecting patients for adjuvant immunotherapy. however, surgically induced inflammation can potentially aid in progression of remaining malignant cells and affect prognosis. the inflammatory marker neutrophil-to-lymphocyte ratio (nlr) is also a negative prognostic and predictive marker in serval malignancies, among melanoma. however, it is not yet established if slnb induces a systemic inflammatory response.

Eligibility criteria:
inclusion criteria: * adult (\>18 years of age) * diagnosed with invasive cutaneous melanoma * eligible for slnb (melanoma stage ≥ t1b) * obtained signed informed consent exclusion criteria: * pregnancy

Keywords: melanoma surgery neutrophil-to-lymphocyte ratio surgical inflammation
topical raplixa for surgical bleeding in children

Conditions: Surgical Bleeding

Summary: the purpose of the study is to determine if raplixa plus gelfoam is better than gelfoam alone in stopping mild to moderate bleeding in children having surgery.


Eligibility criteria:
before surgery inclusion criteria: * was at least 36 weeks gestational age at birth (if an infant less than 6 months old) and is no older than 17 years at time of treatment * has a legal representative (parent or guardian) who signed an institutional review board (irb)-approved informed consent document * if at least 7 years old or appropriate age as defined by local regulations, may be required to sign an irb-approved assent document * is scheduled to undergo one of the surgical procedures described in the protocol * if female and of child-bearing potential, subject has negative pregnancy test on the day of surgery (baseline) * if a sexually active male or female of reproductive potential, agrees to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits during surgery inclusion criteria: * has mild or moderate bleeding/oozing * has tbs surface area no more than 100 cm\^2 * has not received any whole blood, fresh frozen plasma (ffp), cryoprecipitate, or platelets within 24 hours prior to study drug (packed red blood cell (prbc) transfusions are allowed) * had no complication during surgery other than bleeding which, in the opinion of the investigator, may interfere with the assessment of efficacy or safety exclusion criteria: * has any clinically significant laboratory or vital sign value, chronic disease state, or congenital coagulation disorder (eg, hemophilia a or b) that the investigator determines could interfere with the assessment of efficacy or pose a safety risk to the participant * is unwilling to receive blood products * has known antibodies or hypersensitivity to porcine gelatine, raplixa or any of it's components, or other thrombin preparations or coagulation factors * has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety of the participant or compliance with study procedures, including protocol-defined limits on participating in other clinical studies

Keywords: surgical hemostasis bleeding fibrin sealant fibrinogen thrombin spray dried
quality assurance of administering methylphenidate in adults with attention deficit hyperactivity disorder (adhd) - qumea

Conditions: Attention Deficit Hyperactivity Disorder

Summary: investigation of efficacy of high-dose extended-release methylphenidate in adults with adhd, compared with a placebo


Eligibility criteria:
inclusion criteria: * patient treated as out-patient * score of 85 or greater in iq-test (mwt-b) * diagnosis of adhd according adhs-cl (dsm iv) and wraadds \> 35 points * adhd symptoms have existed since childhood (wurs-k \>= 30) * body mass index \>= 20 and body weight \< 130 kg * willing to eat breakfast and lunch * patient is willing and able to come to the observation appointments * written consent of the patient to participate in the study exclusion criteria: * treatment with psychostimulants in the past two weeks before screening * shift work or night work * alcohol, medication or drug dependency in the past six months or manifest drug abuse * diagnosis of a psychosis (skid-i) * epileptic attacks in the past * eeg result which suggests epilepsy * acute depressive episode according to icd-10 f32.2 and icd-10 f32.3 (beck-depression-inventory \> 18) * illness with schizophrenic symptoms (skid-i) * acute manic episode, bipolar disorder(skid-i) * diagnosis of a tic disorder * acute anorexia * acute prominent panic disorder and generalised anxiety (skid-i) * clinically relevant kidney disorders * creatinine \> 1,5 x upper norm-range * clinically relevant liver disorder * sgot and/or sgpt \> 2 x upper norm-range * pathological ecg-finding * qtc \> 450 msec in male, qtc \> 470 msec in female * high blood pressure (anamnesis or blood pressure \> 140/90 mm hg at screening) * known acclusive arterial disease * angina pectoris (anamnesis or ecg-finding) * cardiac arrhythmias (anamnesis or ecg-finding) * khk (anamnesis or ecg-finding) * post heart-attack status (anamnesis or ecg-finding) * post stroke status * known elevated intra-ocular pressure * known enlarged prostates * latent and manifest hyperthyreosis * tsh \< lower norm-range * patient with a terminal disease (e.g. cancer) * participation in a clinical study within the past 30 days * participation in this study at an earlier point in time * simultaneous participation in another clinical trial * women of child-bearing age without adequate contraception (contraceptives, intrauterine device , no sexual intercourse) * pregnancy (positive pregnancy test) or lactation period

Keywords: adhd attention deficit hyperactivity disorder adult methylphenidate hydrochloride medikinet retard controlled clinical trial safety randomized, double-blind, placebo-controlled trial treatment central nervous system stimulants therapeutic uses
safety study of elvucitabine in hiv-1 subjects

Conditions: HIV Infections

Summary: the purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.

this is a 14 day on treat/14 day off treatment randomized, double blind viral kinetic study of elvucitabine versus lamivudine administered once daily to hiv infected subjects with a documented m184v variant.

Eligibility criteria:
inclusion criteria: * hiv infected, clinically stable, adults * hivrna 5000 -150,000, cd4 100 * genotypically documented m184v variant * receiving stable art. exclusion criteria: * hep b * hiv-1 genotype for 4 protease inhibitors * hiv-1 genotype positive for 2 nnrti mutations * previous therapy with system myelosuppressive potential within 3 months of study start * use of epogen or neupogen * history of cirrhosis * alcohol or drug dependence * inability to tolerate oral medication * women who are pregnant or breast feeding

Keywords: hiv-1 treatment experienced
ulcer prevention study in post gastric bypass patients

Conditions: Marginal Ulcers

Summary: this research is to determine which medication, zegerid (omeprazole/sodium bicarbonate) or pepcid ac (famotidine), works best at reducing the chance that a patient will get an ulcer after gastric bypass surgery.

the purpose of this research is to evaluate information about the control of gastric acid in post gastric bypass surgery patients. goal is to determine which medication best reduces the incidence of anastomotic ulcers post-operatively.

Eligibility criteria:
inclusion criteria: * subject is age ≥ 18 years * patient meets the criteria for laparoscopic gastric bypass surgery * females only: patient is willing to take a urine pregnancy test exclusion criteria: * subject allergic to omeprazole or famotidine * patient receiving antifungal (i.e. ketoconazole or itraconazole) * hepatic insufficiency * history of crohns disease * history of zollinger-ellison disease * patient received an investigational drug within 30 days of enrollment * patient currently enrolled in another research project * females only: pregnancy or plan on becoming pregnant during the next 14 weeks

Keywords: gastric bypass surgery anastomosis, roux-en-y complication, postoperative
detection of hemodynamic changes in tbi population with functional near infrared spectroscopy

Conditions: Traumatic Brain Injury

Summary: the goal of this project is to develop a test to assess frontal lobe function using a rapid, inexpensive, objective, and standardized method, without the need for expertise in cognitive test administration. such methods would be particularly helpful in traumatic brain injury (tbi), where objective measures are needed, and would greatly expand the capacity to make such assessments in clinical practice and research.


Eligibility criteria:
inclusion criteria: * able to read, write, speak and understand english * history of having sustained a tbi prior to enrollment. evidence will be any one of the following 3 criteria: 1. gcs 3 - 12 2. post-traumatic amnesia \> 24 hours 3. tbi-related abnormality on neuroimaging (either ct or mri). (some missing information about the initial injury (i.e. documentation of initial gcs) is not necessarily exclusionary if the bulk of the available history is indicative that the patient suffered a tbi and meets the inclusion criteria) exclusion criteria: * multiple sclerosis, pre- or co-existing * stroke (other than stroke at the time of tbi) * pre-existing developmental disorder * pre-existing epilepsy * pre-existing major depressive disorder * pre-existing schizophrenia

Keywords: traumatic brain injury functional near infrared spectroscopy
validation the effectiveness of graded training in the multicomponent physical exercise program (vivifrail) among senile care center residents: a randomized controlled study

Conditions: Frailty; Physical Inactivity; Aging

Summary: this study evaluates the effectiveness of the vivifrail multicomponent physical exercise program among elderly residents with different levels of frailty in long-term care centers. a 12-week intervention will be conducted in randomly assigned experimental and control groups. outcomes include physical performance, fall risk, grip strength, calf circumference, and icope function.


Eligibility criteria:
inclusion criteria: * age ≥70, resident in ltc center, ambulatory, physician-cleared for training exclusion criteria: * conditions listed in vivifrail exclusion criteria (e.g., acute mi, unstable angina, recent fractures, uncontrolled hypertension, etc.)
playing games to learn about children's vaccines project

Conditions: HPV; COVID-19; Vaccine-Preventable Diseases

Summary: this proposed study aims to conduct timely research that promotes vaccine confidence and vaccination of two strongly recommended vaccines with suboptimal uptake rates: human papillomavirus (hpv) and covid-19 in vulnerable and underserved youth aged 11-14.

the study objectives are: objective 1: assess feasibility (participation rate, retention, involvement, satisfaction) of two game-based interventions targeting hpv and covid-19 vaccination. objective 2: conduct a pilot rct with three conditions (arm 1: hpv game-based intervention; arm 2: covid-19 game-based intervention; arm 3: usual care). the investigators will explore patterns of pre- to post-intervention change in theoretical mediators and vaccine intent, and explore levels of vaccine intent and uptake in 90 parent-child dyads of unvaccinated youth aged 11-14.

Eligibility criteria:
inclusion criteria: * child sample: individuals who (1) are aged 11-14 years, (2) have not received the 1st dose of hpv or covid-19 vaccine, (3) can speak and read english, and (4) when approached, both parent and the child indicate that they do not plan or cannot decide whether the child will receive the hpv or covid-19 vaccine. * parent sample: individuals who (1) are the parent/caregiver of the participating child, (2) agree to participate in the research activities. if more than one child in the same family is eligible for the study, the oldest one who has not received the hpv or covid-19 vaccination will be recruited. exclusion criteria: * individuals who do not meet inclusion criteria or refuse to provide consent/assent.

Keywords: adolescent game intervention